Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1205007.RAl3af01Db1eFLgLrTxUvtlx9v9mV_td2V96bJqrWIowo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1205007.RAl3af01Db1eFLgLrTxUvtlx9v9mV_td2V96bJqrWIowo130_assertion type Assertion NP1205007.RAl3af01Db1eFLgLrTxUvtlx9v9mV_td2V96bJqrWIowo130_head.
- NP1205007.RAl3af01Db1eFLgLrTxUvtlx9v9mV_td2V96bJqrWIowo130_assertion description "[These data provide novel insights in immunological control mechanisms preserved in this leukemia subtype and suggest that not only treatment with chemicals such as HDAC inhibitors but also retained in vivo response to CD40 ligation contributes to improved immune surveillance in these patients which may add to a superior relapse-free survival observed particularly in the presence of other risk factors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1205007.RAl3af01Db1eFLgLrTxUvtlx9v9mV_td2V96bJqrWIowo130_provenance.
- NP1205007.RAl3af01Db1eFLgLrTxUvtlx9v9mV_td2V96bJqrWIowo130_assertion evidence source_evidence_literature NP1205007.RAl3af01Db1eFLgLrTxUvtlx9v9mV_td2V96bJqrWIowo130_provenance.
- NP1205007.RAl3af01Db1eFLgLrTxUvtlx9v9mV_td2V96bJqrWIowo130_assertion SIO_000772 25062112 NP1205007.RAl3af01Db1eFLgLrTxUvtlx9v9mV_td2V96bJqrWIowo130_provenance.
- NP1205007.RAl3af01Db1eFLgLrTxUvtlx9v9mV_td2V96bJqrWIowo130_assertion wasDerivedFrom befree-2016 NP1205007.RAl3af01Db1eFLgLrTxUvtlx9v9mV_td2V96bJqrWIowo130_provenance.
- NP1205007.RAl3af01Db1eFLgLrTxUvtlx9v9mV_td2V96bJqrWIowo130_assertion wasGeneratedBy ECO_0000203 NP1205007.RAl3af01Db1eFLgLrTxUvtlx9v9mV_td2V96bJqrWIowo130_provenance.